CVI Pharmaceuticals has presented preclinical data on their thyroid hormone receptor beta (THRB) selective agonist CVI-2742 for the potential treatment of NASH. Selective activation of the THRB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback